Étude LEADER - liraglutide et événements cardiovasculaires : analyse complémentaire chez les sujets âgés ≥ 75 ans
Sign Up to like & getrecommendations! Published in 2018 at "Annales d'Endocrinologie"
DOI: 10.1016/j.ando.2018.06.203
Abstract: Objectifs Les patients diabetiques âges sont particulierement a risque en raison des comorbidites associes et plus fragiles au regard des effets secondaires des medicaments. Cette analyse post-hoc de l’etude LEADER a ete menee chez des… read more here.
Keywords: leader; liraglutide; leader liraglutide; chez les ... See more keywords
The preventive effect of liraglutide on the lipotoxic liver injury via increasing autophagy.
Sign Up to like & getrecommendations! Published in 2019 at "Annals of hepatology"
DOI: 10.1016/j.aohep.2019.06.023
Abstract: INTRODUCTION AND OBJECTIVES The incidence of non-alcoholic fatty liver disease (NAFLD) is increasing. Previous studies indicated that Liraglutide, glucagon-like peptide-1 analogue, could regulate glucose homeostasis as a valuable treatment for Type 2 Diabetes. However, the… read more here.
Keywords: lc3 beclin1; liraglutide; hepg2 cells; beclin1 atg7 ... See more keywords
Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial.
Sign Up to like & getrecommendations! Published in 2019 at "Atherosclerosis"
DOI: 10.1016/j.atherosclerosis.2019.07.007
Abstract: BACKGROUND AND AIMS Atherosclerosis in obesity and type 2 diabetes (T2DM) is associated with low-grade inflammation (LGI) and dyslipidemia, where especially small, dense lipoprotein particles are atherogenic. The glucagon-like peptide-1 receptor agonist, liraglutide, reduces cardiovascular… read more here.
Keywords: newly diagnosed; metformin; statin; coronary artery ... See more keywords
Effects of liraglutide plus phentermine in adults with obesity following 1 year of treatment by liraglutide alone: A randomized placebo-controlled pilot trial.
Sign Up to like & getrecommendations! Published in 2019 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2019.03.005
Abstract: BACKGROUND This pilot study evaluated whether adding phentermine to liraglutide would induce further weight loss in participants who had previously lost weight with liraglutide alone. SUBJECTS/METHODS Participants were 45 adults with obesity (75.6% female, 55.6%… read more here.
Keywords: trial; liraglutide; liraglutide alone; placebo ... See more keywords
Liraglutide inhibits gallstone formation.
Sign Up to like & getrecommendations! Published in 2021 at "Metabolism: clinical and experimental"
DOI: 10.1016/j.metabol.2021.154728
Abstract: BACKGROUND & AIMS Cholesterol gallstone disease (CGD) is a common gastrointestinal disease. Liraglutide, an analog of glucagon-like peptide 1, has been approved to treat type 2 diabetes. Clinical studies have suggested a potential role of… read more here.
Keywords: fxr; cgd; cholesterol; liraglutide ... See more keywords
Cardiovascular safety of liraglutide for the treatment of type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Drug Safety"
DOI: 10.1080/14740338.2017.1313225
Abstract: ABSTRACT Introduction: Liraglutide is a GLP-1 RA that is an option for treatment of T2DM. Typical of all new glucose-lowering agents, its CV safety profile is of great interest. Areas covered: This article outlines the… read more here.
Keywords: treatment; safety; liraglutide; cardiovascular safety ... See more keywords
Liraglutide and Exercise Synergistically Attenuate Vascular Inflammation and Enhance Metabolic Insulin Action in Early Diet-induced Obesity.
Sign Up to like & getrecommendations! Published in 2023 at "Diabetes"
DOI: 10.2337/db22-0745
Abstract: Inflammation-induced vascular insulin resistance is an early event in diet-induced obesity and contributes to metabolic insulin resistance. To examine whether exercise and glucagon-like peptide 1 (GLP-1) receptor agonism, alone or in combination, modulate vascular and… read more here.
Keywords: inflammation; liraglutide; obesity; metabolic insulin ... See more keywords
Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
Sign Up to like & getrecommendations! Published in 2020 at "Frontiers in Cell and Developmental Biology"
DOI: 10.3389/fcell.2020.602574
Abstract: Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been demonstrated to alleviate non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanism has not been fully elucidated. Increasing evidence suggests that autophagy is involved in the… read more here.
Keywords: hepatic steatosis; autophagy lysosomal; treatment; liraglutide ... See more keywords
Renoprotective Effect of Liraglutide Is Mediated via the Inhibition of TGF-Beta 1 in an LLC-PK1 Cell Model of Diabetic Nephropathy
Sign Up to like & getrecommendations! Published in 2022 at "Current Issues in Molecular Biology"
DOI: 10.3390/cimb44030072
Abstract: Background: Recently published research demonstrated direct renoprotective effects of the glucagon-like peptide-1 receptor agonist GLP 1 RA, but the relevant molecular mechanisms are still not clear. The aim of this research was to assess the… read more here.
Keywords: cell; effect; hg30; liraglutide ... See more keywords
Bolus Injection of Liraglutide Raises Plasma Glucose in Normal Rats by Activating Glucagon-like Peptide 1 Receptor in the Brain
Sign Up to like & getrecommendations! Published in 2022 at "Pharmaceuticals"
DOI: 10.3390/ph15070904
Abstract: Diabetes is commonly treated with glucagon-like peptide-1 receptor (GLP-1R) agonists including liraglutide and others. However, liraglutide was found to raise plasma glucose levels in normal rats. The current study aims to determine how liraglutide causes… read more here.
Keywords: injection liraglutide; plasma glucose; liraglutide; glucagon like ... See more keywords